Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 90100 vs Vehicle in Psoriasis Vulgaris
NCT01866163Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Jun 2013
- Primary completion
- Oct 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of calcipotriol in Psoriasis vulgaris (PV) (2 arms), sponsored by LEO Pharma. Primary endpoint: Treatment Success According to Investigator's Global Assessment at 4 weeks. Started Jun 2013; status: completed.
02
Drugs
calcipotriol
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT01866163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01866163.